Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
Barclays Maintains Equal-Weight on Humacyte, Raises Price Target to $0.6
Humacyte (HUMA) Q3 2026 Earnings Call Transcript
Humacyte, Inc. Q3 2026 Earnings Call Summary
Humacyte Q3 Earnings Call Highlights
Humacyte, Inc. (HUMA) Q3 2026 Earnings Call Transcript
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target
Humacyte Q3 2026 Earnings Call Transcript
Humacyte Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $1.028M Beat $766.000K Estimate
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.